ACAD

Acadia Pharmaceuticals Inc. (ACAD) | Rumor.io

Acadia Pharmaceuticals

ACAD

Attention (50-day avg)0%

Attention rank (50-day avg)#1,631

Bullish sentiment (50-day avg)90%

Price to earnings ratio9.08

Market capitalization3.5B

Earnings per share2.23

Dividend yield (TTM)—

Revenue (annual)1.1B

Net income (annual)391M

Social

What share of all stock conversation is about ACAD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Sep 25

ACADIA Pharmaceuticals' ($ACAD) remlifanserin shows potential in treating Alzheimer's disease psychosis, with Phase 2 trial results indicating significant efficacy at the 60 mg dose.
Analysts have reassessed the near-term prospects and valuation of $ACAD after the company's latest trial update, with some cutting price targets, including Citi's Yigal Nochomovitz, who trimmed his price target to $33 from $40.
Despite a 12% drop in shares after an unfavorable drug trial result, $ACAD's Phase 3 data still holds promise, with some analysts believing it will be successful in both Alzheimer's Disease Psychosis and Lewy Body Dementia Psychosis Phase 3s.

Generated by AI

Sentiment

Of the messages about ACAD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	97.06% -2.94	84.29% +24.29	84.52% -15.48	91.52% +11.95
Bearish	2.94% new	15.71% -24.29	15.48% +15.48	8.48% -11.95

Bullish· Dec 13

$ACAD has the potential to be bought out, which could lead to significant gains for shareholders, given the company's successful FDA-approved drugs and large holder status.
A Citigroup analyst has initiated coverage on $ACAD with a Buy rating and a $38 price target, indicating strong market potential.
$ACAD has seen significant price increases, up 76% this year, and is gaining momentum, with a recent patent win removing a key overhang and paving the way for further growth.

Bearish· Mar 11

ACADIA Pharmaceuticals Inc. announced a Phase 3 trial failure for its schizophrenia treatment, pimavanserin, with no plans to conduct further trials.
The company's cash reserves are substantial at $438M, but may not be enough to sustain the business in the face of a failed drug.
The recent failure of Daybue, another ACADIA drug, resulted in a significant stock price decline, suggesting a pattern of poor performance for the company's products.

Generated by AI

Topics

Of the messages about ACAD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	45.78%	65.91%	62.6%
Technical Analysis	0%	6.02%	3.79%	9.49%
Analysts	0%	25.3%	15.91%	24.25%
Macro	0%	22.89%	14.39%	2.57%
Earnings	0%	0%	0%	1.08%
Controversies	0%	0%	0%	0%

Earnings· May 4

ACADIA Pharmaceuticals Inc. reported Q1 earnings of -$0.44 EPS and $48.87M in revenue, beating estimates.
The company's revenue of $48.9M topped Street forecasts, and its sales guidance for the year was reaffirmed at $255-270M.
ACADIA Pharmaceuticals also beat EPS loss estimates by $0.12 and revenue estimates by $1.31M, according to Estimize consensus.

Analysts· Mar 14

ACADIA Pharmaceuticals Inc. ($ACAD) received a new price target of $33.00 from Cantor Fitzgerald, indicating a 68% upside potential.
Analysts at Citigroup, HC Wainwright, and Jefferies Financial Group raised their price targets for ACADIA Pharmaceuticals to $21.00, $28.00, and $15.00, respectively.
Several analysts, including those at Cantor Fitzgerald, HC Wainwright, and RBC Capital, maintained their "buy" or "outperform" ratings for ACADIA Pharmaceuticals, with some increasing their price targets.

Announcements· Jun 26

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing authorization for Acadia Pharmaceuticals' (ACAD) Daybue (trofinetide) for the treatment of Rett syndrome.
This positive opinion is a significant reversal from the CHMP's previous negative stance, which was confirmed in ACAD's Q1 2026 10-Q filing.
The European Commission is expected to make a final decision on the marketing authorization in the coming months, which could make Daybue the first approved treatment for Rett syndrome symptoms in Europe.

Technical Analysis· Mar 10

$ACAD is expected to break through $27.50 resistance, potentially leading to a significant price increase.
An obvious bull flag has formed, indicating a strong likelihood of a price increase past the $27.50 resistance level.
The stock has shown resilience during a morning pullback, suggesting consolidation and a potential swing upward.

Generated by AI

Community

Of the messages about ACAD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	12.24%	54.95%	62.45%	54.73%
Newcomers	87.76%	45.05%	37.55%	45.27%

Regulars· Sep 25

Acadia Pharmaceuticals' remlifanserin shows potential in treating Alzheimer's disease psychosis, with Phase 2 trial results indicating significant efficacy at the 60 mg dose and a favorable safety profile.
Analysts have lowered their price targets for $ACADIA Pharmaceuticals, with Citizens lowering its price target from $36.00 to $33.00 and maintaining its Market Outperform rating.
The company's latest trial update has put the spotlight on remlifanserin's development path, prompting analysts to reassess its near-term prospects and valuation, with some experts expressing concerns about the challenging indication and the potential for a "meh" prescription behavior.

Newcomers· Sep 24

The focus is on Acadia Pharmaceuticals' ($ACAD) experimental treatment for Prader-Willi syndrome failing to meet its primary endpoint in a late-stage study, leading to disappointing results.
Newcomers are drawn to the stock's potential for growth, with some analysts, such as Wells, suggesting it should be up at least 20% despite the failure.
The company's board changes, driven by Engine Capital, have also caught the attention of some investors, leading to a rise in Acadia Pharmaceuticals' shares.

Generated by AI

SAN DIEGO, September 28, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled "Methods and Compositions for Treatment of Rett Syndrome." The Notice of Allowance indicates that the USPTO has determined that the application meets the requirements for patentability, and the patent is expected to issue following completion of standard administrati

1d agoYahoo Finance

Acadia Pharmaceuticals stock price target lowered to $33 by H.C. Wainwright

1d agoInvesting.com

Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop

Acadia Pharmaceuticals has seen its share price fall sharply over the past month, and that pullback is pushing investors to ask whether the current valuation still lines up with what the business is earning today. With the stock under pressure and expectations around its drug pipeline shifting, the key issue is how much of those earnings are already reflected in the price. The share price is down 29.0% over the past month. That puts fresh focus on whether recent weakness has moved Acadia...

3d agoYahoo Finance Singapore

Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ)

4d agoSeeking Alpha

Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says

Acadia Pharmaceuticals' (ACAD) favorable risk-reward remains intact despite remlifanserin narrowly m

4d agoYahoo Finance

Also Discussed

Investors talking about ACAD also mention

#	Name	Attention
1	Sarepta Therapeutics, Inc.SRPT	0%-0.01
2	Exelixis Inc.EXEL	0%-0.03
3	Celldex Therapeutics IncCLDX	0%0
4	RDUS - Radius Recycling, Inc.	——
5	iShares Biotechnology ETFIBB	0.01%0
6	Alnylam Pharmaceuticals, Inc.ALNY	0%0
7	Puma Biotechnology, Inc.PBYI	0%0
8	ITCI - Intra-Cellular Therapies, Inc.	——
9	Agios Pharmaceuticals, Inc.AGIO	0%0
10	SGEN - Seagen Inc.	——

Acadia Pharmaceuticals Inc.

Healthcare
Biotechnology

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases. The company’s commercial portfolio includes treatments for Parkinson’s disease psychosis and Rett syndrome, reflecting its emphasis on neuropsychiatric and neuro-rare conditions with limited treatment options. Acadia Pharmaceuticals Inc. also maintains a clinical and research pipeline targeting additional unmet needs in neuroscience, including programs in Alzheimer’s disease psychosis, Lewy body dementia psychosis, and other rare or underserved patient populations. Based in San Diego, California, the company serves as a specialized player in the healthcare market, combining drug development, regulatory expertise, and commercialization capabilities to support patients, caregivers, and healthcare providers across its therapeutic areas.

Website

Location

12830 El Camino Real

San Diego, CA, 92130

United States

Social

What share of all stock conversation is about ACAD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Sep 25

ACADIA Pharmaceuticals' ($ACAD) remlifanserin shows potential in treating Alzheimer's disease psychosis, with Phase 2 trial results indicating significant efficacy at the 60 mg dose.
Analysts have reassessed the near-term prospects and valuation of $ACAD after the company's latest trial update, with some cutting price targets, including Citi's Yigal Nochomovitz, who trimmed his price target to $33 from $40.
Despite a 12% drop in shares after an unfavorable drug trial result, $ACAD's Phase 3 data still holds promise, with some analysts believing it will be successful in both Alzheimer's Disease Psychosis and Lewy Body Dementia Psychosis Phase 3s.

Generated by AI

Sentiment

Of the messages about ACAD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	97.06% -2.94	84.29% +24.29	84.52% -15.48	91.52% +11.95
Bearish	2.94% new	15.71% -24.29	15.48% +15.48	8.48% -11.95

Bullish· Dec 13

$ACAD has the potential to be bought out, which could lead to significant gains for shareholders, given the company's successful FDA-approved drugs and large holder status.
A Citigroup analyst has initiated coverage on $ACAD with a Buy rating and a $38 price target, indicating strong market potential.
$ACAD has seen significant price increases, up 76% this year, and is gaining momentum, with a recent patent win removing a key overhang and paving the way for further growth.

Bearish· Mar 11

ACADIA Pharmaceuticals Inc. announced a Phase 3 trial failure for its schizophrenia treatment, pimavanserin, with no plans to conduct further trials.
The company's cash reserves are substantial at $438M, but may not be enough to sustain the business in the face of a failed drug.
The recent failure of Daybue, another ACADIA drug, resulted in a significant stock price decline, suggesting a pattern of poor performance for the company's products.

Generated by AI

Topics

Of the messages about ACAD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	45.78%	65.91%	62.6%
Technical Analysis	0%	6.02%	3.79%	9.49%
Analysts	0%	25.3%	15.91%	24.25%
Macro	0%	22.89%	14.39%	2.57%
Earnings	0%	0%	0%	1.08%
Controversies	0%	0%	0%	0%

Earnings· May 4

ACADIA Pharmaceuticals Inc. reported Q1 earnings of -$0.44 EPS and $48.87M in revenue, beating estimates.
The company's revenue of $48.9M topped Street forecasts, and its sales guidance for the year was reaffirmed at $255-270M.
ACADIA Pharmaceuticals also beat EPS loss estimates by $0.12 and revenue estimates by $1.31M, according to Estimize consensus.

Analysts· Mar 14

ACADIA Pharmaceuticals Inc. ($ACAD) received a new price target of $33.00 from Cantor Fitzgerald, indicating a 68% upside potential.
Analysts at Citigroup, HC Wainwright, and Jefferies Financial Group raised their price targets for ACADIA Pharmaceuticals to $21.00, $28.00, and $15.00, respectively.
Several analysts, including those at Cantor Fitzgerald, HC Wainwright, and RBC Capital, maintained their "buy" or "outperform" ratings for ACADIA Pharmaceuticals, with some increasing their price targets.

Announcements· Jun 26

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing authorization for Acadia Pharmaceuticals' (ACAD) Daybue (trofinetide) for the treatment of Rett syndrome.
This positive opinion is a significant reversal from the CHMP's previous negative stance, which was confirmed in ACAD's Q1 2026 10-Q filing.
The European Commission is expected to make a final decision on the marketing authorization in the coming months, which could make Daybue the first approved treatment for Rett syndrome symptoms in Europe.

Technical Analysis· Mar 10

$ACAD is expected to break through $27.50 resistance, potentially leading to a significant price increase.
An obvious bull flag has formed, indicating a strong likelihood of a price increase past the $27.50 resistance level.
The stock has shown resilience during a morning pullback, suggesting consolidation and a potential swing upward.

Generated by AI

Community

Of the messages about ACAD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	12.24%	54.95%	62.45%	54.73%
Newcomers	87.76%	45.05%	37.55%	45.27%

Regulars· Sep 25

Acadia Pharmaceuticals' remlifanserin shows potential in treating Alzheimer's disease psychosis, with Phase 2 trial results indicating significant efficacy at the 60 mg dose and a favorable safety profile.
Analysts have lowered their price targets for $ACADIA Pharmaceuticals, with Citizens lowering its price target from $36.00 to $33.00 and maintaining its Market Outperform rating.
The company's latest trial update has put the spotlight on remlifanserin's development path, prompting analysts to reassess its near-term prospects and valuation, with some experts expressing concerns about the challenging indication and the potential for a "meh" prescription behavior.

Newcomers· Sep 24

The focus is on Acadia Pharmaceuticals' ($ACAD) experimental treatment for Prader-Willi syndrome failing to meet its primary endpoint in a late-stage study, leading to disappointing results.
Newcomers are drawn to the stock's potential for growth, with some analysts, such as Wells, suggesting it should be up at least 20% despite the failure.
The company's board changes, driven by Engine Capital, have also caught the attention of some investors, leading to a rise in Acadia Pharmaceuticals' shares.

Generated by AI

Acadia Pharmaceuticals

Social

Sep 25

Bullish· Dec 13

Bearish· Mar 11

Earnings· May 4

Analysts· Mar 14

Announcements· Jun 26

Technical Analysis· Mar 10

Regulars· Sep 25

Newcomers· Sep 24

Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

Acadia Pharmaceuticals stock price target lowered to $33 by H.C. Wainwright

Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop

Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ)

Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says

Also Discussed

Acadia Pharmaceuticals Inc.

Company Information

Location

Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

Acadia Pharmaceuticals stock price target lowered to $33 by H.C. Wainwright

Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop

Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ)

Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says

Also Discussed

Social

Sep 25

Bullish· Dec 13

Bearish· Mar 11

Earnings· May 4

Analysts· Mar 14

Announcements· Jun 26

Technical Analysis· Mar 10

Regulars· Sep 25

Newcomers· Sep 24